Patents Assigned to Amgen
  • Autoinjector
    Patent number: 10398854
    Abstract: An injector such as a needle-type autoinjector having a flexible flange disposed at an injection end of the injector for stretching or pinching the skin of the injection site. The flexible flange may be removably attached to the injector or integrated into the injector during manufacturing. Further, an injector having a palm button disposed at an activation end of the injector for activating an injection cycle of the injector. The palm button may be removably attached to the injector or integrated into the injector during manufacturing. Still further, a holding device for one-handed operation of an injector, the holding device having a sleeve and at least one hand rest coupled to the sleeve, the sleeve and hand rest providing ergonomic holding and operation of the injector. Still further, autoinjector needle shield having an enlarged, rounded lip for contacting the skin at the injection site.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: September 3, 2019
    Assignee: AMGEN INC.
    Inventors: Valerie M. Fenster, Stephanie Toy, Mark Ka Lai Lee, Denise Meyer
  • ANTIBODIES DIRECTED TO HER-3 AND USES THEREOF
    Publication number: 20190263930
    Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.
    Type: Application
    Filed: October 9, 2018
    Publication date: August 29, 2019
    Applicants: DAIICHI SANKYO EUROPE GMBH, AMGEN INC.
    Inventors: MIKE ROTHE, MARTIN TREDER, ERIC BORGES, LARRY L. GREEN
  • DUAL RECEPTOR ANTAGONISTIC ANTIGEN-BINDING PROTEINS AND USES THEREOF
    Publication number: 20190256605
    Abstract: This disclosure related to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.
    Type: Application
    Filed: March 5, 2019
    Publication date: August 22, 2019
    Applicant: AMGEN INC.
    Inventors: Huiquan Han, Xiaolan Zhou, Qing Chen, Mei-Mei Tsai
  • METHODS FOR TREATING OR PREVENTING MIGRAINE HEADACHE
    Publication number: 20190256607
    Abstract: The present invention relates to methods of migraine prophylaxis using anti-CGRP receptor antibodies or binding fragments. In particular, methods for preventing or reducing the occurrence of migraine headache in a patient in need thereof comprising administering to the patient an anti-CGRP receptor or binding fragment according to specific dosage regimens are disclosed. Pharmaceutical compositions and administration devices comprising anti-CGRP receptor antibodies or binding fragments for use in the methods are also described.
    Type: Application
    Filed: February 27, 2019
    Publication date: August 22, 2019
    Applicant: AMGEN INC.
    Inventors: Hong Sun, Eduardo Dunayevich, Robert A. Lenz, Gabriel Vargas
  • Alkyl dihydroquinoline sulfonamide compounds
    Patent number: 10383866
    Abstract: The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: August 20, 2019
    Assignee: AMGEN INC.
    Inventors: Matthew Weiss, Thomas Dineen, Benjamin C. Milgram
  • Human Antigen Binding Proteins That Bind to a Complex Comprising Beta-Klotho and an FGF Receptor
    Publication number: 20190248906
    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing B-Klotho, and or FGF21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising ?-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to a complex comprising ?-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c.
    Type: Application
    Filed: February 22, 2019
    Publication date: August 15, 2019
    Applicant: Amgen, Inc.
    Inventors: Yang LI, Jennitte LeAnn STEVENS, Chadwick Terence KING, Ian Nevin FOLTZ, Gunasekaran KANNAN, Junming YIE, Shaw-Fen Sylvia HU
  • LOW-VISCOSITY ANTIGEN BINDING PROTEINS AND METHODS OF MAKING THEM
    Publication number: 20190233543
    Abstract: The present invention concerns a method for preparing antigen binding proteins with reduced viscosity. The method proceeds by replacing residues in high viscosity variable domain subfamilies with residues in correlating low viscosity subfamilies. The method further comprises substituting residues in the Fc domain with residues associated with low viscosity and adding charged residues to the C-terminus of the Fc domain. The present invention further concerns antigen binding proteins produced by this method.
    Type: Application
    Filed: September 28, 2017
    Publication date: August 1, 2019
    Applicant: AMGEN INC.
    Inventors: Neeraj Jagdish AGRAWAL, Pavel BONDARENKO, Joon Hoi HUH, Andrew NICHOLS, Da REN, Richard SMITH, Riki STEVENSON
  • Methods of treating cardiovascular disease with an ASGR inhibitor
    Patent number: 10358497
    Abstract: Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: July 23, 2019
    Assignee: AMGEN INC.
    Inventors: Paul Nioi, Jun Zhang, Yang Li
  • PAC1 ANTIBODIES AND USES THEREOF
    Publication number: 20190218279
    Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
    Type: Application
    Filed: January 11, 2019
    Publication date: July 18, 2019
    Applicant: AMGEN INC.
    Inventors: Neeraj Jagdish AGRAWAL, Irwin CHEN, Su CHONG, Bryna FUCHSLOCHER, Kevin GRAHAM, Agnes Eva HAMBURGER, Mark Leo MICHAELS, Christopher MOHR, Derek E. PIPER, Kenneth William WALKER, Zhulun WANG, Cen XU
  • Bromotriazole intermediates
    Patent number: 10344016
    Abstract: Bromotriazole intermediates are useful in the synthesis of agonists of the APH receptor.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: July 9, 2019
    Assignee: AMGEN INC.
    Inventors: Paul John Dransfield, Zice Fu, Julie Anne Heath, Jeffrey T. Mihalic, Vatee Pattaropong
  • Stable liquid formulation of AMG 416 (etelcalcetide)
    Patent number: 10344765
    Abstract: A liquid formulation comprising a peptide agonist of the calcium sensing receptor and method of preparing and using the formulation are provided.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: July 9, 2019
    Assignee: Amgen Inc.
    Inventors: Derek Maclean, Qun Yin
  • Potent and selective inhibitors of Nav1.7
    Patent number: 10344060
    Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: July 9, 2019
    Assignee: AMGEN INC.
    Inventors: Justin K. Murray, Jerry Ryan Holder, Malgorzata Wanska, Christopher M. Tegley, James R. Falsey, Elizabeth M. Doherty, Leslie P. Miranda, Kaustav Biswas, Bin Wu, Kelvin Sham, Jason C. Long
  • Polymorphic forms and co-crystals of a c-Met inhibitor
    Patent number: 10344041
    Abstract: Provided herein are novel polymorphic forms and co-crystals of a compound useful in the treatment, prevention, or amelioration of cancer. In particular, the invention provides polymorphs and co-crystals of 6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, which is an inhibitor of c-Met.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: July 9, 2019
    Assignee: Amgen, Inc.
    Inventors: David Bauer, Matthew Bio, Melanie Cooke, Katrina W. Copeland, Matthew Peterson, Michele Potashman, Roman Shimanovich, Helming Tan
  • COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20190201412
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: March 11, 2019
    Publication date: July 4, 2019
    Applicant: AMGEN INC.
    Inventors: Sean P. Brown, Kexue Li, Yunxiao Li, Markian M. Stec
  • Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
    Patent number: 10336820
    Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: July 2, 2019
    Assignee: Amgen Inc.
    Inventors: Thomas Charles Boone, Jonathan Daniel Oliner, Eunkyung Lee
  • STABILIZATION OF FC-CONTAINING POLYPEPTIDES
    Publication number: 20190192628
    Abstract: This disclosure provides polypeptides comprising an antibody Fc region having a deletion of one or more cysteine residues in the hinge region and substitution with a sulfhydryl-containing residue of one or more CH3-interface amino acids. Also, provided are Fc-fusion proteins and antibodies containing said polypeptides, nucleic acids and vectors encoding said polypeptides, along with host cells and methods for making said polypeptides.
    Type: Application
    Filed: March 8, 2019
    Publication date: June 27, 2019
    Applicant: AMGEN INC.
    Inventors: Gunasekaran KANNAN, Jennifer LAVALLEE, Frederick W. JACOBSEN
  • Biomarkers and use of MET inhibitor for treatment of cancer
    Patent number: 10328062
    Abstract: The present invention relates to methods of therapeutic treatment of cancer using selective tyrosine kinase inhibitors and cancer biomarkers, such as MET amplification and high Met expression for patient selection.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: June 25, 2019
    Assignee: Amgen, Inc.
    Inventors: Sean Caenepeel, Angela Coxon, Zhiqiang Du, Paul Hughes, Robert Loberg, Gataree Ngarmchamnanrith, Beate Sable
  • CHIMERIC RECEPTORS TO FLT3 AND METHODS OF USE THEREOF
    Publication number: 20190183931
    Abstract: Antigen binding molecules, chimeric receptors, and engineered immune cells to FLT3 are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the FLT3 antigen binding molecules and engineered immune cells.
    Type: Application
    Filed: March 31, 2017
    Publication date: June 20, 2019
    Applicants: AMGEN INC., KiTE Pharma, Inc.
    Inventors: BAKKER Alice, WU Lawren, ARVEDSON Tara, WILTZIUS J. Jed, RODRIGUEZ Alvarez Ruben
  • Autoinjector with removable cap
    Patent number: D851754
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: June 18, 2019
    Assignee: AMGEN INC.
    Inventors: Margaux Frances Boyaval, Sigrid Moeslinger, Masamichi Udagawa
  • Handheld drug delivery device
    Patent number: D854146
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: July 16, 2019
    Assignee: AMGEN INC.
    Inventors: Brian Stonecipher, Ryan Jerome Ramos, Christian Plambech, Claus Jepsen, Emil Wegger Jensen